Seller record · Telehealth service

MyDrHank

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No dispensing pharmacy is named. The terms state that a current list of pharmacy partners is available on request; the product pages refer to registered or accredited US pharmacies. 2 more criteria also fail; see the table below.

At a glance

MyDrHankTelehealth service

5/8criteria passed

Price: Oral semaglutide from $171 a month; injectable semaglutide from $178 and tirzepatide from $240 a month
Sells: compounded semaglutide, compounded tirzepatide, oral semaglutide, and 2 more
FDA letters: None on file

Visit MyDrHank See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform offering compounded oral and injectable semaglutide, tirzepatide, sermorelin and NAD+ through licensed providers. Its public pages print starting prices but provide the pharmacy list only on request.

Operating entity The public terms and privacy policy identify the service as Dr. Hank or MyDrHank without printing a separate legal entity name.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	MyDrHank's weight loss page; MyDrHank's terms of use page
S2	Prescription gating	PASS	MyDrHank's weight loss page; MyDrHank's compounded semaglutide product page
S3	Pharmacy identification	FAIL	MyDrHank's terms of use page; MyDrHank's compounded semaglutide product page
S4	Compounding disclosure	PASS	MyDrHank's weight loss page; MyDrHank's oral semaglutide product page
S5	Analytical documentation	FAIL	MyDrHank's weight loss page; MyDrHank's peptides page; MyDrHank's terms of use page
S6	Business address	FAIL	MyDrHank's website; MyDrHank's terms of use page; MyDrHank's privacy policy
S7	Price disclosure	PASS	MyDrHank's weight loss page; MyDrHank's sermorelin product page; MyDrHank's NAD+ injection product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe treatment steps describe review by a US-licensed clinician, and the terms state that the provider decides independently whether to prescribe, with no guaranteed prescription.Source: MyDrHank's weight loss page; MyDrHank's terms of use page.

S2PASSThe public steps put a medical questionnaire first, provider review second and delivery after prescribing. The pages describe the consultation as free.Source: MyDrHank's weight loss page; MyDrHank's compounded semaglutide product page.

S3FAILNo dispensing pharmacy is named. The terms state that a current list of pharmacy partners is available on request; the product pages refer to registered or accredited US pharmacies.Source: MyDrHank's terms of use page; MyDrHank's compounded semaglutide product page.

S4PASSThe footer and product pages state that compounded medications are not FDA-approved and distinguish them from the approved formulations studied in the clinical trials quoted on the pages.Source: MyDrHank's weight loss page; MyDrHank's oral semaglutide product page.

S5FAILNo certificate of analysis or lot report is published on the weight-loss, peptide, product, terms or privacy pages examined.Source: MyDrHank's weight loss page; MyDrHank's peptides page; MyDrHank's terms of use page.

S6FAILNo company postal address is printed on the home, terms or privacy pages. The contact link leads to an existing-patient reorder route rather than a public address page.Source: MyDrHank's website; MyDrHank's terms of use page; MyDrHank's privacy policy.

S7PASSThe public catalog prints oral semaglutide from $171 a month, injectable semaglutide from $178, tirzepatide from $240, sermorelin from $137 and NAD+ injections from $155. The displayed starting prices do not establish a dose-specific quote or disclose the billing commitment on these pages.Source: MyDrHank's weight loss page; MyDrHank's sermorelin product page; MyDrHank's NAD+ injection product page.

S8PASSNo FDA warning letter names MyDrHank or Dr. Hank, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, oral semaglutide, sermorelin, NAD+.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+

Visit MyDrHank

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.